Are the Two Human Papillomavirus Vaccines Really Similar A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVReportar como inadecuado




Are the Two Human Papillomavirus Vaccines Really Similar A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Corrigendum A corrigendum for this article has been published. To view the corrigendum, please click here.

Journal of Immunology Research - Volume 2015 2015, Article ID 435141, 13 pages -

Review Article

SaPeRiDoc Unit, Department of Primary Health Care, Regional Health Authority of Emilia-Romagna, Viale Aldo Moro 21, 40127 Bologna, Italy

Office of Chief Scientist, European Centre for Disease Prevention and Control ECDC, 171 83 Stockholm, Sweden

Statistics Unit, Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy

Drug Evaluation Unit, WHO Collaborating Centre for Evidence Based Research Synthesis and Guidelines Development, Regional Health and Social Agency of Emilia-Romagna, Viale Aldo Moro 21, 40127 Bologna, Italy

Received 22 October 2014; Accepted 30 March 2015

Academic Editor: L. Leite

Copyright © 2015 Simona Di Mario et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. When the bivalent and the quadrivalent HPV vaccines were marketed they were presented as having comparable efficacy against cervical cancer. Differences between the vaccines are HPV types included and formulation of the adjuvant. Method. A systematic review was conducted to assess the efficacy of the two vaccines against cervical cancer. Outcomes considered were CIN2+, CIN3+, and AIS. Results. Nine reports 38,419 women were included. At enrolment mean age of women was 20 years, 90% had negative cytology, and 80% were seronegative and-or DNA negative for HPV 16 or 18 naïve women. In the TVC-naïve, VE against CIN2+ was 58% 95% CI: 35, 72; heterogeneity was detected, VE being 65% 95% CI: 54, 74 for the bivalent and 43% 95% CI: 23, 57 for the quadrivalent. VE against CIN3+ was 78% 95% CI: <0, 97; heterogeneity was substantial, VE being 93% 95% CI: 77, 98 for the bivalent and 43% 95% CI: 12, 63 for the quadrivalent. VE in the TVC was much lower. No sufficient data were available on AIS. Conclusions. In naïve girls bivalent vaccine shows higher efficacy, even if the number of events detected is low. In women already infected the benefit of the vaccination seems negligible.





Autor: Simona Di Mario, Vittorio Basevi, Pier Luigi Lopalco, Sara Balduzzi, Roberto D’Amico, and Nicola Magrini

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados